Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Neurotox Res ; 37(1): 77-92, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31332714

RESUMEN

Systemic administration of 3-nitropropionic acid (3-NPA) is commonly used to induce Huntington's disease (HD)-like symptoms in experimental animals. Here, the potential neuroprotective efficiency of rutin and selenium (RSe) co-administration on 3-NPA-induced HD-like symptoms model in mice was investigated. 3-NPA injection evoked severe alterations in redox status, as indicated via increased striatal malondialdehyde and nitric oxide levels, accompanied by a decrease in levels of antioxidant molecules including glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and catalase. Moreover, 3-NPA potentiated inflammatory status by enhancing the production of interleukin-1ß, tumor necrosis factor-α, and myeloperoxidase activity. Pro-apoptotic cascade was also recorded in the striatum as evidenced through upregulation of cleaved caspase-3 and Bax, and downregulation of Bcl-2. 3-NPA activated astrocytes as indicated by the upregulated glial fibrillary acidic protein and inhibited brain-derived neurotrophic factor. Furthermore, perturbations in cholinergic and monoaminergic systems were observed. RSe provided neuroprotective effects by preventing body weight loss, oxidative stress, neuroinflammation, and the apoptotic cascade. RSe inhibited the activation of astrocytes, increased brain-derived neurotrophic factor, and improved cholinergic and monoaminergic transmission following 3-NPA intoxication. Taken together, RSe co-administration may prevent or delay the progression of HD and its associated impairments through its antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory effects.


Asunto(s)
Enfermedad de Huntington/prevención & control , Estrés Oxidativo/efectos de los fármacos , Rutina/farmacología , Selenio/farmacología , Animales , Factor Neurotrófico Derivado del Encéfalo/biosíntesis , Caspasa 3 , Catalasa/metabolismo , Cuerpo Estriado/metabolismo , Regulación hacia Abajo , Sinergismo Farmacológico , Proteína Ácida Fibrilar de la Glía/biosíntesis , Glutatión/metabolismo , Glutatión Peroxidasa/metabolismo , Glutatión Reductasa/metabolismo , Enfermedad de Huntington/inducido químicamente , Enfermedad de Huntington/metabolismo , Interleucina-1beta/biosíntesis , Masculino , Malondialdehído/metabolismo , Ratones , Fármacos Neuroprotectores/farmacología , Óxido Nítrico/metabolismo , Nitrocompuestos , Peroxidasa/metabolismo , Propionatos , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Superóxido Dismutasa/metabolismo , Transmisión Sináptica/efectos de los fármacos , Factor de Necrosis Tumoral alfa/biosíntesis , Regulación hacia Arriba , Proteína X Asociada a bcl-2/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA